Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations Transcript

Omnicell, Inc. (OMCL) Discusses Launch of Titan XT Enterprise Platform and Its Impact on Pharmacy Operations Transcript

Seeking Alpha • Dec 9, 2025

Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management

FORT WORTH, Texas--(BUSINESS WIRE)--Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management.

Business Wire • Dec 8, 2025

OMCL vs. HIMS: Which Stock Should Value Investors Buy Now?

Investors interested in Medical Info Systems stocks are likely familiar with Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Dec 8, 2025

Reasons to Add Omnicell Stock to Your Portfolio Right Now

OMCL's expanding SaaS pipeline, global push and solid solvency highlight growth potential despite rising competition.

Zacks Investment Research • Dec 5, 2025

Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Host Innovation Update and Q&A Session at Upcoming ASHP Midyear Industry Trade Show.

Business Wire • Dec 1, 2025

Wall Street Analysts Think Omnicell (OMCL) Could Surge 30.93%: Read This Before Placing a Bet

The consensus price target hints at a 30.9% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 27, 2025

Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell to Present at the Piper Sandler 37th Annual Healthcare Conference.

Business Wire • Nov 20, 2025

OMCL or HIMS: Which Is the Better Value Stock Right Now?

Investors looking for stocks in the Medical Info Systems sector might want to consider either Omnicell (OMCL) or Hims & Hers Health, Inc. (HIMS). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research • Nov 20, 2025

Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies

FORT WORTH, Texas--(BUSINESS WIRE)--Omnicell Achieves URAC Certification, Strengthening Compliance and Scalability for Health System-Owned Specialty Pharmacies.

Business Wire • Nov 13, 2025

Wall Street Analysts Believe Omnicell (OMCL) Could Rally 34.53%: Here's is How to Trade

The consensus price target hints at a 34.5% upside potential for Omnicell (OMCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research • Nov 10, 2025